Bone drug showdown: which works better for Steroid-Weakened bones?

NCT ID NCT06472050

Completed Disease control Sponsor: Tuen Mun Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at two osteoporosis medications—romosozumab and denosumab—in 54 people who take long-term steroids and have weak bones. Participants first received either romosozumab for 12 months followed by denosumab, or denosumab alone for 24 months. Then everyone stayed on denosumab for another 2 years. The goal was to see how their spine and hip bone density changed over 4 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romosozumab (Evenity) and Denosumab (Prolia)
What this could lead to: If successful, this could show that switching from romosozumab to denosumab maintains or improves bone density better than denosumab alone for people on long-term steroids.
What could go wrong: This is a small, completed extension study with only 54 participants, so results may not apply to everyone. It only measures bone density, not actual fracture reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-INDUCED OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone fracture exogenous Cushing syndrome glucocorticoid-induced osteoporosis osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLUCOCORTICOIDS TOXICITY OSTEOPOROSIS

Contacts and locations

Locations

Department of Medicine, Tuen Mun Hospital

Hong Kong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.